Eculizumab treatment alters the proteometabolome beyond the inhibition of complement
Christopher Nelke(Heinrich Heine University Düsseldorf), Tobias Ruck(BG University Hospital Bergmannsheil Bochum), Niklas Huntemann(Düsseldorf University Hospital), Sven G. Meuth(University Hospital Münster), Saskia Räuber(Düsseldorf University Hospital), Frauke Stascheit(Humboldt-Universität zu Berlin), Stefan Tenzer(Johannes Gutenberg University Mainz), Andreas Roos(University of Duisburg-Essen), Andreas Meisel(Humboldt-Universität zu Berlin), Alice Willison(Düsseldorf University Hospital), Nico Melzer(Düsseldorf University Hospital), Kai Stühler(Düsseldorf University Hospital), Ute Distler(Johannes Gutenberg University Mainz), Marc Pawlitzki(Heinrich Heine University Düsseldorf), Christina B. Schroeter(University of Münster)
Cited by 10
Related Papers
Propionic Acid Shapes the Multiple Sclerosis Disease Course by an Immunomodulatory Mechanism
|Cell|2020|627
Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use
|The Lancet Neurology|2009|581
Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model.
|PubMed|2002|452
Erythropoietin Is a Paracrine Mediator of Ischemic Tolerance in the Brain: Evidence from an<i>In Vitro</i>Model
|Journal of Neuroscience|2002|387